Tag: 200-300

On May 31, 2019, Vadivelu, Saravanan; Rajagopal, Sridharan; Burri, Raghunadha Reddy; Garapaty, Shivani; Sivanandhan, Dhanalakshmi; Thakur, Manish Kumar; Natarajan, Tamizharasan; Swamy, Indu N.; Nagaraju, Nagendra; Kanagaraj, Subramaniam; Mohd, Zainuddin; Sarkar, Sayantani; Samanta, Swapan Kumar; Hariprakash published a patent.Computed Properties of 1774893-22-9 The title of the patent was Preparation of heterocyclic compounds as PRMT5 inhibitors. And the patent contained the following:

The invention relates to compounds of formula I and their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof as PRMT5 inhibitors; their preparation and use in the treatment of and/or prevention of various diseases, including cancer and infectious diseases. Compounds of formula I wherein A is substituted isoquinolinyl, dihydroindenylamino; dashed bond is optional single or double bond; n = 0-1; m = 0-2; p = 1-2; q = 1-3; R1 – R6 are independently H, halo, OH, etc.; R7 is H, C1-6 (un)substituted alkyl, (un)substituted aryl, etc.; R8 is absent, H, halo, C1-6 alkyl, etc.; R10 is H, halo, OH, CN, etc.; X, Y and Z are independently NH and derivatives, O, S, etc.; W and B are independently N and C; and their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, are claimed. Example compound II was prepared by amidation of 6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid with 1-amino-3-(3,4-dihydroisoquinolin-2(1H)-yl)propan-2-ol. The invention compounds were evaluated for their PRMT5 inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value ranged from 0.01-1 渭M. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Computed Properties of 1774893-22-9

The Article related to heterocycle preparation prmt5 inhibitor treatment cancer infection, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Computed Properties of 1774893-22-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On May 31, 2019, Vadivelu, Saravanan; Rajagopal, Sridharan; Burri, Raghunadha Reddy; Garapaty, Shivani; Sivanandhan, Dhanalakshmi; Thakur, Manish Kumar; Natarajan, Tamizharasan; Swamy, Indu N.; Nagaraju, Nagendra; Kanagaraj, Subramaniam; Mohd, Zainuddin; Sarkar, Sayantani; Samanta, Swapan Kumar; Hariprakash published a patent.Synthetic Route of 1774893-22-9 The title of the patent was Preparation of heterocyclic compounds as PRMT5 inhibitors. And the patent contained the following:

The invention relates to compounds of formula I and their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof as PRMT5 inhibitors; their preparation and use in the treatment of and/or prevention of various diseases, including cancer and infectious diseases. Compounds of formula I wherein A is substituted isoquinolinyl, dihydroindenylamino; dashed bond is optional single or double bond; n = 0-1; m = 0-2; p = 1-2; q = 1-3; R1 – R6 are independently H, halo, OH, etc.; R7 is H, C1-6 (un)substituted alkyl, (un)substituted aryl, etc.; R8 is absent, H, halo, C1-6 alkyl, etc.; R10 is H, halo, OH, CN, etc.; X, Y and Z are independently NH and derivatives, O, S, etc.; W and B are independently N and C; and their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof, are claimed. Example compound II was prepared by amidation of 6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid with 1-amino-3-(3,4-dihydroisoquinolin-2(1H)-yl)propan-2-ol. The invention compounds were evaluated for their PRMT5 inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value ranged from 0.01-1 渭M. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Synthetic Route of 1774893-22-9

The Article related to heterocycle preparation prmt5 inhibitor treatment cancer infection, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Synthetic Route of 1774893-22-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On May 15, 2014, Coe, Jotham Wadsworth; Allen, John Arthur; Davoren, Jennifer Elizabeth; Dounay, Amy Beth; Efremov, Ivan Viktorovich; Gray, David Lawrence Firman; Guilmette, Edward Raymond; Harris, Anthony Richard; Helal, Christopher John; Henderson, Jaclyn Louise; Mente, Scot Richard; Nason, Deane Milford, II; O’Neil, Steven Victor; Subramanyam, Chakrapani; Xu, Wenjian published a patent.Formula: C8H7BrN2 The title of the patent was Preparation of heteroaromatic compounds and their use as dopamine D1 ligands for therapy. And the patent contained the following:

The present invention provides, in part, compounds of Formula I (wherein X1 is O or S; Y1 is O, S, or (un)substituted NH; Q1 is Ph, or a N-containing 5-10-membered heterocycloalkyl or heteroaryl, all optionally substituted; RT1 and RT2 are independently H, C1-3-alkyl, cyclopropyl, etc.; R1 is H, F, -C(O)OH, C1-3-fluoroalkyl, etc.; R2 is H, halogen, -CN, -OH, C(O)OH, etc.; R3 and R4 are independently H, C1-6 alkyl, C1-6 haloalkyl, etc.; R5 and R6 are independently H, halogen, -OH, -NO2, -CN, etc.) and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced 尾-arrestin recruitment activity relative to dopamine, D1 agonists interacting significantly with Ser188 but not significantly with Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with both Asp103 and Ser198 of a D1R when binding to the D1R, and their uses in treating neurol., psychiatric and endocrine disorders. Example compound II was prepared in a multistep synthesis that culminated in reaction of intermediate III with 5-bromo-4,6-dimethylpyrimidine. In a human D1 receptor binding assay, II had a Ki of 27.3 nM. The experimental process involved the reaction of 5-Bromo-6-methylimidazo[1,2-a]pyridine(cas: 1346157-13-8).Formula: C8H7BrN2

The Article related to preparation heteroaromatic compound dopamine d1 ligand therapy, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Formula: C8H7BrN2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Clark, Robert L.; Pessolano, Arsenio A.; Shen, Tsung-Ying; Jacobus, David P.; Jones, Howard; Lotti, Victor J.; Flataker, Lars M. published an article in 1978, the title of the article was Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.Quality Control of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one And the article contains the following content:

One hundred-thirty imidazo[4,5-b]pyridin-2-ones (I, R = H or alkyl, X = H, halo, alkyl, NH2, etc.) and 60 triazolo[4,5-b]pyridines (II, X = H, halo, alkyl, alkoxy, NO2, etc.) were prepared, eg by cyclizing 3-nitro-2-anilinopyridines with COCl2, urea, or NaNO2. I and II increased the pain threshold of both the inflammed and the normal foot in a modified Randall-Selitto test. I (R = H, X = 3,4-OCH2O), I (R = allyl, X = 3,4-OCH2O), I (R = CHMe2, X = 3,4-OCH2O), II (X = H) and II (X = F) were the most active compounds The analgesic activity of I was superior to that of codeine or D-propoxyphene, while showing no narcotic characteristics. Some I and II were effective in the carrageenin edema test. The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).Quality Control of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

The Article related to phenylimidazopyridinone preparation analgesic, phenyltriazolopyridine preparation analgesic, imidazopyridinone phenyl preparation analgesic, triazolopyridine phenyl preparation analgesic and other aspects.Quality Control of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On November 15, 2017, Cook, James; Zusi, F. Christopher; Hill, Matthew D.; Fang, Haiquan; Pearce, Bradley; Park, Hyunsoo; Gallagher, Lizbeth; McDonald, Ivar M.; Bristow, Linda; Macor, John E.; Olson, Richard E. published an article.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one The title of the article was Design and synthesis of a novel series of (1’S,2R,4’S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor. And the article contained the following:

We describe an efficient and convergent synthesis of a series of (1’S,2R,4’S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes], such as I (R = H, 5-Cl, 6-Me, etc.) displaying potency for the α7 nicotinic acetylcholine receptor (nAChR) and good selectivity vs. the related 5-HT3A receptor. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

The Article related to azaspiro benzoimidazooxazole bicyclooctane preparation alpha 7 nicotinic acetylcholine receptor, 5-ht(3a) receptor, schizophrenia, spirooxazolines, α7 nicotinic acetylcholine receptor and other aspects.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On December 2, 2016, Youn, So Won; Kim, Yi Hyun published an article.Name: 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one The title of the article was Pd(II)/Ag(I)-Promoted One-Pot Synthesis of Cyclic Ureas from (Hetero)Aromatic Amines and Isocyanates. And the article contained the following:

A simple and facile one-pot reaction has been developed to afford a diverse range of N,N’-disubstituted benzimidazolones and imidazopyridinones containing two differently substituted N atoms. A cooperative Pd(II)/Ag(I) system promotes the sequential addition/intramol. C-H amidation reaction of (hetero)aromatic amines and isocyanates, leading to the formation of two C-N bonds. A mechanism involving radical intermediates generated by single-electron transfer (SET) in the presence of a Ag2CO3 oxidant and Pd(OAc)2 Lewis acid is proposed. This protocol offers an operationally easy, simple, and robust approach with the use of readily available starting materials, good functional group tolerance, and high efficiency. The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).Name: 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

The Article related to disubstituted benzimidazolone imidazopyridinone preparation palladium silver promoted sequential reaction, cyclic urea preparation addition amidation hetero aromatic amine isocyanate and other aspects.Name: 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Clark, Robert L.; Pessolano, Arsenio A.; Shen, Tsung-Ying; Jacobus, David P.; Jones, Howard; Lotti, Victor J.; Flataker, Lars M. published an article in 1978, the title of the article was Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.Quality Control of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one And the article contains the following content:

One hundred-thirty imidazo[4,5-b]pyridin-2-ones (I, R = H or alkyl, X = H, halo, alkyl, NH2, etc.) and 60 triazolo[4,5-b]pyridines (II, X = H, halo, alkyl, alkoxy, NO2, etc.) were prepared, eg by cyclizing 3-nitro-2-anilinopyridines with COCl2, urea, or NaNO2. I and II increased the pain threshold of both the inflammed and the normal foot in a modified Randall-Selitto test. I (R = H, X = 3,4-OCH2O), I (R = allyl, X = 3,4-OCH2O), I (R = CHMe2, X = 3,4-OCH2O), II (X = H) and II (X = F) were the most active compounds The analgesic activity of I was superior to that of codeine or D-propoxyphene, while showing no narcotic characteristics. Some I and II were effective in the carrageenin edema test. The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).Quality Control of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

The Article related to phenylimidazopyridinone preparation analgesic, phenyltriazolopyridine preparation analgesic, imidazopyridinone phenyl preparation analgesic, triazolopyridine phenyl preparation analgesic and other aspects.Quality Control of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On November 15, 2017, Cook, James; Zusi, F. Christopher; Hill, Matthew D.; Fang, Haiquan; Pearce, Bradley; Park, Hyunsoo; Gallagher, Lizbeth; McDonald, Ivar M.; Bristow, Linda; Macor, John E.; Olson, Richard E. published an article.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one The title of the article was Design and synthesis of a novel series of (1’S,2R,4’S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor. And the article contained the following:

We describe an efficient and convergent synthesis of a series of (1’S,2R,4’S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes], such as I (R = H, 5-Cl, 6-Me, etc.) displaying potency for the α7 nicotinic acetylcholine receptor (nAChR) and good selectivity vs. the related 5-HT3A receptor. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

The Article related to azaspiro benzoimidazooxazole bicyclooctane preparation alpha 7 nicotinic acetylcholine receptor, 5-ht(3a) receptor, schizophrenia, spirooxazolines, α7 nicotinic acetylcholine receptor and other aspects.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On December 2, 2016, Youn, So Won; Kim, Yi Hyun published an article.Name: 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one The title of the article was Pd(II)/Ag(I)-Promoted One-Pot Synthesis of Cyclic Ureas from (Hetero)Aromatic Amines and Isocyanates. And the article contained the following:

A simple and facile one-pot reaction has been developed to afford a diverse range of N,N’-disubstituted benzimidazolones and imidazopyridinones containing two differently substituted N atoms. A cooperative Pd(II)/Ag(I) system promotes the sequential addition/intramol. C-H amidation reaction of (hetero)aromatic amines and isocyanates, leading to the formation of two C-N bonds. A mechanism involving radical intermediates generated by single-electron transfer (SET) in the presence of a Ag2CO3 oxidant and Pd(OAc)2 Lewis acid is proposed. This protocol offers an operationally easy, simple, and robust approach with the use of readily available starting materials, good functional group tolerance, and high efficiency. The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).Name: 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

The Article related to disubstituted benzimidazolone imidazopyridinone preparation palladium silver promoted sequential reaction, cyclic urea preparation addition amidation hetero aromatic amine isocyanate and other aspects.Name: 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On March 13, 1979, Clark, Robert L.; Pessolano, Arsenio A.; Shen, Tsung-Ying published a patent.Quality Control of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one The title of the patent was Imidazopyridin-2-ones and pharmaceutical compositions and methods of treatment. And the patent contained the following:

Imidazopyridines I [R = H, C2-6 alkenyl, C1-7 alkyl (substituted with C3-6 cycloalkyl, C1-5 alkoxy, or OH), C4-7 cycloalkyl; R1, R2, R4 = H, 5- or 6-F, 5- or 6-Cl, 5- or 6-C1-5 alkoxycarbonylamino; R1R2 = OCR5R6O (R5, R6 = H, alkyl)] were prepared by several methods. Also prepared were 3-heterocyclyl analogs of I and 2-thiono analogs of I. I and their analogs were analgesics, antipyretics, and antiinflammatory agents (no data). Thus, refluxing 2-chloro-3-nitropyridine with 3,4-(OCH2O)C6H3NH2 in NaOAc-AcOH 5 h gave nitropyridine II (R7 = NO2) which was hydrogenated over Pd/C in MeOH and the diamine II (R7 = NH2) cyclized with COCl2 overnight at room temperature to give I (R = R4 = H, R1R2 = 3,4-OCH2O), which was converted into a variety of I (R = alkyl, alkenyl, acyl, R1R2 = OCH2O, R4 = H). The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).Quality Control of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

The Article related to analgesic imidazopyridinone preparation, antipyretic imidazopyridinone preparation, antiinflammatory imidazopyridinone preparation, imidazopyridinone pharmaceutical preparation, aminoanilinopyridine cyclization phosgene and other aspects.Quality Control of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem